Immunotech Laboratories, Inc.

(A Development Stage Company)

Financial Information

Quarter End Report

September 30, 2014

(OTC Pink: IMMB) OTC Pink

(Report prepared on November 14, 2014 for the Quarter and nine month period ended September 30, 2014)

All information contained in this Quarterly Report has been compiled to meet the OTC Pink Basic Disclosure Guidelines to qualify for the OTC Pink Current Information tier.

1.) Name of issuer and its predecessor

Immunotech Laboratories, Inc., a Nevada corporation (hereinafter referred to as the “Company”, “we”, “us”, or “our” or “the Issuer”).

a) Incorporated in the State of Nevada on April 11, 2000 under the name of “Earthnet Media.com”.

b) On April 8, 2001, changed its name to “Earthnet Media,Inc.”

c) On October 18, 2006, changed its name to “International Technology Systems, Inc.” and traded under the symbol ITSY

d) On December 15, 2008, the Company effected a reverse merger with Immunotech Laboratories, Inc. and on December 18, 2008 changed its name to Immunotech Laboratories, Inc. trading under the symbol IMMB.

2. Company Headquarters Address

120 W Pomona Ave

Monrovia, CA 91016

Phone: (818) 409-9091

Fax: (626) 703-4172

Email: info@immunotechlab.com

Website: http//www.immunotechlab.com

IR Contact : same as above

3. Security Information

Trading Symbol: IMMB

Title and Class: Immunotech Laboratories Common Stock

Immunotech Laboratories Series A Preferred

Immunotech Laboratories Series B Preferred

CUSIP Number: 45254f203

Common Stock Stated or Par Value $.001

Common Stock Authorized @ 9/30/2014 800,000,000

Common Stock Outstanding @ 9/30/2014 533,464,967

Series A Preferred Shares Authorized @ 9/30/2014 50,000,000

Series A Preferred Shares Issued @ 9/30/2012 50,000,000

Series B Preferred Shares Authorized @ 9/30/2014 200,000,000

Series B Preferred Shares Authorized @ 9/30/2014 200,000,000

Transfer Agent: Pacific Stock Transfer Company

4045 South Spencer Street, Suite 403

Las Vegas, NV 89119

Phone: (702) 361-3033

Transferred Agent Registered: Yes

List any restrictions on the transfer of security: None

Trading suspensions by SEC: None

Stock Splits: On June 21, 2006 the Company approved a forward split of five common shares for one common shares

On February 26, 2009 the Company effected a one for one hundred reverse split on its common shares

Additional Information: In the calendar year 2012 the Company increased the authorized common shares to 800,000,000 with par value of $0.001 per share.

On September 14, 2012 the Company created a Preferred Class of 200,000,000 Series B with par value of $0.001 per share.

4) Issuance History for last two years

Immunotech Laboratories, Inc.
(Formally International Technology Systems, Inc.)
For the Years Ending December 31, 2013 and December 31, 2012 and
Nine Months ended September 30, 2014

Item	Preferred Series A Par Value $.001	Preferred Series B Par Value $.001	Common Stock Par Value $.001
Balance at December 31, 2012	50,000,000	200,000,000	433,496,325
Shares Issued in 2013			19,322,222
Balance at December 31, 2013	50,000,000	200,000,000	452,818,547
Balance at March 31, 2014	50,000,000	200,000,000	452,818,547
Shares issued in the Nine Months Ended 9/30/2014			80,946,420
Balance at September 30, 2014	50,000,000	200,000,000	533,464,967

In the nine month period ended September 30, 2014 the Company issued the following Restricted Common shares in exempt transactions to the listed entities;

Vrej Khacachadurin April2014 shares issued 3,000,000 in settlement of a claim for services.

LA Financial Equities April 2014 shares issued 22,625,900 in settlement of claim for services.

Blaine Nabors May 2014 shares issued 750,000 for services rendered.

Elie Sakayan May 2014 shares issued 40,000,000 for services associated with field trials in Bulgaria.

Blaine Nabors July 2014 shares issued 7,404,400 for services rendered under employment contract

Camelot Financial Group, Inc. shares issued 3,766,120 for services rendered under consulting contract

Uncommoncents, Inc. shares issued 3,400,000 for services rendered under consulting contract

In the year ending December 31, 2013 the Company issued the following Common Shares during the period in exempt transactions to the listed entities;

Volen Sideov January 2013 shares issued 3,000,000 under a subscription agreement.

Mandjoukov SJSC January 2013 shares issued 500,000 under a subscription agreement.

Todd Hart April 2013 shares issued 500,000 for payment made directly to vendor.

Alie Chang September 2013 shares issued 6,000,000 for extension of terms on $300,000.00 Note Payable.

World Financial Capital September 2013 shares issued 722,222 in settlement of claim for services.

Dimitar Savov September and October 2013 shares issued 8,000,000 Field Trial Cost in Bulgaria.

In the year ending December 31, 2012 the Company issued the following Common Shares during the period in exempt transactions to the listed entities;

MT Rose Corporation May through September 2012 shares issued 200,000,000 under a subscription agreement.

Serzhik Kirakosyan June 2012 shares issued 50,000,000 for settlement of claim.

Daniel Valchanov May 2012 shares issued 3,050,000 under a subscription agreement.

Maurice Nazarian September 2012 shares issued 1,500,000 under a subscription agreement.

Harry H. Zhabilov July 2012 shares issued 11,078,000 for services rendered.

Roger Pawson July 2012 shares issued 6,000,000 for services rendered.

Ara Gahnime July and August 2012 shares issued 11,490,500 for services rendered.

Dimitar Savov September 2012 shares issued 15,000,000 for services rendered.

Reed Wallace September 2012 shares issued 1,500,000 under a subscription agreement.

Mariya Radivoeva September 2012 shares issued 5,000,000 under a subscription agreement.

Blaine Nabors October 2012 shares issued 150,000 for services rendered.

For Your Information Inc. November 2012 shares issued 7,428,571 for services rendered.

Carlos Garcia TTEE Noprob Trust November 2013 shares issued 15,000 for services rendered.

Hambarsum Kestenian May 2012 shares issued 2,000,000 under a subscription agreement.

National Financial LLC September 2012 shares issued 50 for services rendered.

In the year ending December 31, 2012 the Company issued the following Preferred Shares for services rendered during the period to the listed entities;

Harry H. Zarbilov September 2012 Preferred Series A shares issued 44,000,000 for services rendered.

Harry H. Zhabilov September 2012 Preferred Series B shares issued 190,000,000 for services rendered.

5) Financial Statements; Attached

6) Business information

A) Immunotech Laboratories Inc. a Nevada Corporation incorporated on April 11, 2000, is an organization with full indefinite licensing rights of the Irreversible Pepsin Fraction (IPF) peptide molecule for the specific treatment of the HIV/AIDS indication. The Company is dedicated to the commercialization of these License rights of the IPF for the treatment of Aids and Hepatitis C as well as potential other treatments for life threatening diseases. IPF is a peptide molecule that has a strong affinity to bind with the HIV virus' peptide components identified as gp41 and gp120 antigens, rendering them as super antigens, and taking away from them their stealthiness and their capability to destroy the immune system. In addition to this mechanism of action, IPF will also enhance and upgrade the immune system components and criteria, as such resulting in a double impact approach of both behaving as a novel fusion inhibition treatment as well as an immuno-modulator. Immunotech Laboratories Inc., in contrast to other biotech start-ups is based on a proven technological foundation and has scientifically demonstrated that its novel molecule IPF for the treatment of HIV/AIDS is a viable alternative and complimentary treatment product.

Technology Summary

The immune system has components that bind and present antigens to cells that are capable of initiating a response to those antigens. CD1d CD 56 molecules are a family of highly conserved antigen-presenting proteins that bind lipids and glycolipids, resulting in activation of natural killer T-cells (NKT cells) to elicit protective immunity against the immunogen.

We have isolated IPF that is the most extensively studied CD 56 ligand to date. We have tested these compounds for their ability to stimulate human NKT cell lines, secretion of key cytokines such as IFN- IL 2 and IL-12, and activate autologous dendritic cells, as well as binding to CD1d and the invariant T-cell receptor. A lead compound, IPF, emerged from these studies and this protein exhibits a stronger adjuvant effect in various HIV vaccine platforms in mice. IPF also provides a protective adjuvant effect with a candidate HIV and HCV vaccine.

While the majority of the studies performed focus on the potential of the IPF as a vaccine adjuvant, it is foreseeable that the compounds could also be used as a potential immunotherapeutic to treat cancer, infectious diseases, and autoimmune diseases.

B) The Company was organized on April 11, 2000 as a Nevada Corporation.

C) The Company's primary SIC Code is 541711.

The Company's Secondary SIC Code is 541990.

D) Fiscal year end: December 31 calendar year

E) The Company is currently in the research and development stage of operations and is in the process of finalizing field test and starting Clinical test through a Bulgarian subsidiary of which the Company owns 49%.

F) The Company is a 49% owner of Immunotech Laboratories BG a company organized on October 11, 2012 under the laws of the Country of Bulgaria. This entity was organized to conduct Clinical trials of the Company's treatments on twenty patients in Bulgaria. The Investment is recorded on the balance sheet as of December 31, 2013 and March 31, 2014. The operations are not consolidated with the Company's results of operation. The Company is holder of exclusive licensing agreement of the US patent numbers 7,479,538 and 8,066,982. Immunotech Laboratories BG is the vehicle that the Company is attempting to commercialize the treatments developed under these patents in Bulgaria.

7) Facilities

Immunotech Laboratories, Inc. operates out of a 1,655 sq. ft. facility located in Monrovia, CA in Hamby Industrial Park under a two year lease expiring on March 31, 2015. All lease payments are current under the lease. The President Harry Zhabilov is guarantor on the lease. The Company currently employs 1 full time individual.

8A) Officers, Directors and Control Persons

Officers: Harry H. Zhabilov, President

Directors: Harry H. Zhabilov, Chairman

Valentine Iordanov Dimitrov

Control Person: Harry H. Zhabilov owner of Series A Preferred 44,000,000 Shares

Series B Preferred 190,000,000 Shares and common shares 6,198,000

8B) Legal

1. None
2. None
3. None
4. None

8C) Beneficial Owners

1) Harry H. Zhabilov,

120 W Pomona Ave Monrovia, CA 91016

Series A Preferred 40,000,000 Shares

Series B Preferred 190,000,000 Shares

Common Shares directly owned 6,198,000

Common Shares Beneficially owned through controlling interest;

Bra Investment Group LLC. 5,400,000

Diamond Investment, LLC 5,400,000

La Meridian Investment Fund, LLC 5,400,000

2) MT Rose Corporation

Represented by; Chrisos Hrizostomoy

PO Box 146, Road Town,

Tartola, British Virgin Islands Cypress Island

Common Shares owned 120,000,000 Common shares

3) Elie Sakayan

1146 N Central Ave

Glendale, CA 91202
Common Shares Owned 40,115,239

4) Dimitar Savov

61 Nishava STR

Sofua, BULGARIA

Common Shares Owned 77,000,000

Series B Preferred Owned 10,000,000

9) Third Party Providers

Legal

Joseph L. Pittera

Law Offices of Joseph L. Pittera

2214 Torrance Boulevard

Suite 101

Torrance, California 90501

Tel (310) 328-3588

Fax (310) 328-3063

E-mail: jpitteralaw@gmail.com

Auditor

None

Public Relations Consultant

None

Other Advisors

Camelot Financial Group, LLC

2851 South Valley View

Las Vegas, NV 89102

10. Officer Certification

The issuer shall include certifications by the chief executive officer and chief financial officer of the issuer (or any other persons with different titles, but having the same responsibilities).

The certifications shall follow the format below:

I, Harry H. Zhabilov, certify that:

1. I have reviewed this Initial Information Disclosure Statement as of September 30, 2014 of Immunotech Laboratories, Inc.;

2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and

3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

Date: November 14, 2014

/s/Harry H. Zhabilov

____

President & Chief Science Officer

Immunotech Laboratories, Inc.

Financial Statements

For the three and nine months ended September 30, 2014

(Unaudited)

Immunotech Laboratories, Inc.
(Formally International Technology Systems, Inc.)
Balance Sheets
September 30, 2014 and December 31, 2013

(Unaudited)		**9/30/2014**		**12/31/2013**
Assets				
Current assets:				
Cash	$	1,286	$	633
Total current assets	$	-	$	633
Plant, Property and Equipment, net	$	341,790	$	354,051
Intangible Assets	$	10,013,860	$	10,013,860
Investment in Immunotech Laboratories BG	$	200,000	$	200,000
Total assets	$	10,556,936	$	10,568,544
Liabilities and Stockholders' Equity				
Current liabilities:				
Accounts payable	$	15,000	$	-
Accrued wages	$	693,670	$	553,267
Accrued interest	$	58,304	$	41,303
Other current liabilities	$	1,550,000	$	1,550,000
Due to shareholders	$	725,223	$	708,579
Total current liabilities	$	3,042,196	$	2,853,149
Long term debt	$	1,645,524	$	1,945,524
Total liabilities	$	4,687,720	$	4,798,673
Stockholders' equity				
Series A Preferred stock, $.001 par value; 50,000,000 shares authorized and issued and outstanding at September 30, 2014 and December 31, 2013. Series B Preferred, $.001par value 200,000,000 authorized and issued at September 30, 2014 and December 31, 2013.	$	250,000	$	250,000
Common stock, $.001 par value; authorized 800,000,000 and 533,464,967 shares and 433,496,325 shares issued and outstanding at September 30, 2014 and December 31, 2013 and 2012.	$	533,465	$	452,518
Additional paid-in capital	$	7,938,344	$	7,608,665
Retained Earnings /(Deficit)	$	(2,852,593)	$	(2,541,312)
Total stockholders 'deficiency	$	5,869,216	$	5,769,871
Total liabilities and stockholders’ equity	$	10,556,936	$	10,568,544

See accompanying notes to financial statements

Immunotech Laboratories, Inc.
(Formally International Technology Systems, Inc.)
Statements of Operations

For the Three and Six Months Ended June 30, 2014 and June 30, 2013

(Unaudited)

	Nine Months Ended		Three Months Ended	
	9/30/2014	9/30/2013	9/30/2014	9/30/2013
Revenue				
Costs of sales	$ 272,903	$ 354,779	$ 72,300	$ 120,941
Gross profit	$ (272,903)	$ (354,779)	$ (72,300)	$ (120,941)
Expenses:				
General and administrative	$ 76,490	$ 44,580	$ 54,707	$ 7,362
Depreciation	$ 12,261	$ 10,761	$ 4,087	$ 3,587
Total expenses	$ 88,751	$ 55,341	$ 58,794	$ 10,949
Income (loss) from continuing operations before other (income) and expense	$ (361,654)	$ (410,120)	$ (131,094)	$ (131,890)
Interest expense, net of interest income	$ 17,001	$ 17,001	$ 5,667	$ 5,667
Other (income) expense	$ 52,626	14,444	$	14,444
Total other (income) and expense	$ 69,627	$ 31,445	$ 5,667	$ 20,111
Income (loss) from continuing operations before income taxes	$ (431,281)	$ (441,565)	$ (136,761)	$ (152,001)
Income taxes				
Net income (loss)	$ (431,281)	$ (441,565)	$ (136,761)	$ (152,001)

See accompanying notes to financial statements

Immunotech Laboratories, Inc.
(Formally International Technology Systems, Inc.)
Consolidated Statements of Stockholders' Equity
For the Periods Ending September, 30, 2014, December 31, 2013 and December 31, 2012

Item	Preferred Shares A	Par Value .001	Preferred Shares B	Par Value .001	Common Stock	Par Value .001	Additional Paid in Capital	Accumulated Deficit
Bal. at 12-31-12	50,000,000	$50,000	200,000,000	$200,000	433,496,325	$ 433,496	$7,421,693	$(1,759,032)
Shares Issued in 2013					19,022,222	$ 19,022	$ 366,972	
Net Loss 12-31-13								$ (662,280)
Balance at 12-31-13	50,000,000	$50,000	200,000,000	$200,000	452,518,547	$ 452,518	$7,788,665	$(2,421,312)
Net Loss 3-30-14								$ (98,538)
Bal. at 3-31-14	50,000,000	$50,000	200,000,000	$200,000	452,518,547	$ 452,518	7,788,665	$(2,519,851)
Shares Iss. in Qtr 6-30-14					66,375,900	$ 66,376	$ 33,750	
Net Loss 6-30-14								$ (195,981)
Bal. at 6- 30-14	50,000,000	$50,000	200,000,000	$200,000	518,894,447	$ 518,894	$7,822,415	$(2,715,832)
Shares Iss. in Qtr 9-30-14					14,570,520	$ 14,571	$ 115,929	
Net Loss 9-30-14								$ (136,761)
Bal. at 9- 30-14	50,000,000	$50,000	200,000,000	$200,000	533,464,967	$533,464.42	$7,938,344	$(2,852,593)

See notes to financial statements

Immunotech Laboratories, Inc.
(Formally International Technology Systems, Inc.)
Statement of Cash Flow
For the Three and Nine Months Ended September 30, 2014 and September 30, 2013

(Unaudited)	Nine Months Ended		Nine Months Ended	
	9/30/2014		9/30/2013	
OPERATING ACTIVITIES				
Net Income	$	(431,281)	$	(441,565)
Adjustments to reconcile Net Income				
to net cash provided by operations:				
Accounts Payable	$	15,000		
Accrued Interest	$	17,001	$	17,001
Accrued Wages Payable	$	140,403	$	214,932
Net cash provided by Operating Activities	$	(258,877)	$	(209,632)
INVESTING ACTIVITIES				
Accumulated Depreciation	$	12,261	$	10,761
Equipment			$	(11,000)
Net cash provided by Investing Activities	$	12,261	$	(239)
FINANCING ACTIVITIES				
Investor Loans	$	16,643	$	172,841
Common Shares Issued	$	230,626	$	340,994
Decrease in Long Term Debt			$	(300,000)
Net cash provided by Financing Activities	$	247,269	$	213,835
	$	653	$	3,964
Cash at beginning of period	$	633	$	489
Cash at end of period	$	1,286	$	4,453

See accompanying notes to financial statements

Immunotech Laboratories, Inc.
(formerly International Technology Systems, Inc.)
Notes to the Financial Statements
The Nine Months Ended September 30, 2014 and Year Ended December 31, 2013
(Unaudited)

1. Organization

Immunotech Laboratories, Inc. (the “registrant”, “Company,” “we”, “us”, “our”, or “Immunotech”) (IMMB) is the successor entity to International Technology Systems, Inc. (“ITSY”), a Nevada corporation, which was established in to 2000. In 2009 Immunotech Laboratories, Inc. acquired the Company in a reverse merger with Immunotech being the surviving entity. The Company is a calendar year corporation.

From 2000 to 2009 the Company operated as a research and development company in the Telecommunication Industry, primarily with International Telecommunication firms. In 2009 after the reverse merger with Immunotech the Company re-focused its efforts on Research and Development in the Bio-Tech Field as a drug development company committed to the commercialization of its proprietary proteins as IRREVERSIBLE PEPSIN FRACTION (IPF) ITV-1 for the treatment of debilitating infectious disease such as HIV and Hepatitis Type C. These drugs have not been approved by the FDA but the Company has begun pre-clinical trial testing. The Company has also began the final phase to start clinical trials in Bulgaria through a minority owned entity, Immunotech Laboratories, BG (“ILBG”) which IMMB owns 49%.

In pursuit of this strategy, on December, 2009 Immunotech Laboratories, Inc. Corp. (the “Registrant,” Immunotech,” or the “Company”) entered into a Licensing Agreement (the "Agreement"), with the Zhavilov Trust, a California Trust (“Z Trust” or the “Seller”) and the Trustees of the Z Trust (“Trustees”). Pursuant to the terms of the Agreement, IMMB agreed to pay $1,550,000.00 Licensing fee to the Trust for exclusive rights to the Patent for proteins to be used to develop a drug treatment for HIV. The exclusivity is for a period of 20 years with approximately 16 years remaining.

2. Basis of Presentation

The financial statements as of and for the nine months ended September 30, 2014 and year ended December 31, 2013 have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) for financial reporting. These statements, in the opinion of management, include all adjustments (consisting of normal recurring adjustments and accruals) necessary for a fair statement for the periods presented.

3. Summary of Significant Accounting Policies

In July 2009, the FASB Accounting Standards Codification (the "Codification") officially became the single source of authoritative nongovernmental U.S. GAAP, superseding existing FASB, American Institute of Certified Public Accountants, Emerging Issues Task Force, and related accounting literature. Going forward, only one level of authoritative GAAP will exist. All other accounting literature will be considered non-authoritative.

Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statement and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from the estimates.

Cash and Cash Equivalents

For financial statement presentation purposes, those short-term, highly liquid investments with original maturities of three months or less are considered to be cash or cash equivalents.

Accounts Receivable

The Company does not have Accounts Receivable at this stage of development of the its product but expects at the completion of field testing of the treatments and approval of the FDA will extend credit to its customers in the normal course of business and performs ongoing credit evaluations of its customers, maintaining allowances for potential credit losses which, when realized, have been within management's expectations. The allowance method will be used to account for uncollectible amounts. The evaluation is inherently subjective, and it will require estimates that are susceptible to significant revision as more information becomes available. Allowance for doubtful accounts was $0 for both 9-30-2014 and 12-31-2013.

Revenue Recognition

The Company did not have revenues in the nine month period ending September 30, 2014 or year ending December 31, 2013.

Property, Plant and Equipment

Property and equipment are reported at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. Lives for property, plant and equipment are as follows: machinery and equipment—5 to 15 years; furniture and fixtures—3 to 10 years; computer hardware and software 3 to 7 years. Routine maintenance costs are expensed as incurred. Expenditures for renewals and betterments are capitalized. The cost and related accumulated depreciation of assets retired or sold are removed from the accounts and gains or losses are recognized in operations. For the nine month period ending September 30, 2014 and year ending December 31, 2013, the Company recorded $12,261 and $14,348 in depreciation expense, respectively.

Valuation of Intangibles and Other Long Lived Assets

The recoverability of long-lived assets, including equipment and intangible assets, is reviewed when events or changes in circumstances occur that indicate that the carrying value of the asset may not be recoverable. The assessment of possible impairment is based on the ability to recover the carrying value of the asset from the expected future pre-tax cash flows (undiscounted and without interest charges) of the related operations. If these cash flows are less than the carrying value of such asset, an impairment loss is recognized for the difference between estimated fair value and carrying value. The primary measure of fair value is based on discounted cash flows. The measurement of impairment requires management to make estimates of these cash flows related to long-lived assets, as well as other fair value determinations.

Fair Value of Financial Instruments

Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of December 31, 2013. The respective carrying value of certain on-balance sheet financial instruments approximated their fair values. These financial instruments include cash and cash equivalents, accounts receivable, accounts payable, line of credit, and accrued expenses. Fair values were assumed to approximate carrying values for these financial instruments since they are short-term in nature and their carrying amounts approximate fair values or they are receivable or payable on demand.

Stock Based Compensation

Stock based awards are accounted for according to the provisions of FASB ASC 718. Our primary type of share-based compensation consists of stock options. We use the Black-Scholes option pricing model in valuing options. The inputs for the valuation analysis of the options include the market value of the Company's common stock, the estimated volatility of the Company's common stock, the exercise price of the warrants and the risk free interest rate.

Fair Value Measurements

FASB ASC 820 defines fair value and establishes a framework for measuring fair value and establishes a fair value hierarchy which prioritizes the inputs to the inputs to the valuation techniques. Fair value is the price that would be received to sell an asset or amount paid to transfer a liability in an orderly transaction between market participants at the measurement date. A fair value measurement assumes that the transaction to sell the asset or transfer the liability occurs in the principal market for the asset or liability or, in the absence of a principal market, the most advantageous market. Valuation techniques that are consistent with the market, income or cost approach, as specified by FASB ASC 820, are used to measure fair value.

Fair Value Hierarchy

FASB ASC 820 specifies a hierarchy of valuation techniques based upon whether the inputs to those valuation techniques reflect assumptions other market participants would use based upon market data obtained from independent sources (observable inputs), or reflect the Company's own assumptions of market participant valuation (unobservable inputs). In accordance with FASB ASC 820, these two types of inputs have created the following fair value hierarchy:

Level 1 - Quoted prices in active markets that are unadjusted and accessible at the measurement date for identical, unrestricted assets or liabilities.

Level 2 - Quoted prices for identical assets and liabilities in markets that are not active, quoted prices for similar assets and liabilities in active markets or financial instruments for which significant inputs are observable, either directly or indirectly.

Level 3 - Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.

FASB ASC 820 requires the use of observable market data if such data is available without undue cost and effort.

The Company measures fair value as an exit price using the procedures described for all assets and liabilities measured at fair value. When available, the Company uses unadjusted quoted market prices to measure fair value and classifies such items within Level 1. If quoted market prices are not available, fair value is based upon internally developed models that use, where possible, current market-based or independently-sourced market parameters such as interest rates and currency rates. Items valued using internally generated models are classified according to the lowest level input or value driver that is significant to the valuation. Thus, an item may be classified in Level 3 even though there may be inputs that are readily observable. If quoted market prices are not available, the valuation model used generally depends on the specific asset or liability being valued. The determination of fair value considers various factors including interest rate yield curves and time value underlying the financial instruments.

Income Taxes

Deferred tax assets and liabilities are recognized for temporary differences between the financial reporting basis and the tax basis of our assets and liabilities. Deferred taxes are recognized for the estimated taxes ultimately payable or recoverable based on enacted tax laws. Allowances are recorded if recovery is uncertain.

Earnings per Common Share

Basic net loss per share is computed using the weighted average number of common shares outstanding during the period. Basic and diluted earnings per share are the same as outstanding options are antidilutive. Dilutive common equivalent shares consist of options to purchase common stock (only if those options are exercisable and at prices below the average share price for the period) and shares issuable upon the conversion of the Company's securities.

Impairment

Intangible assets with estimable lives and other long-lived assets are reviewed for impairment annually or whenever events or changes in circumstances indicate that the carrying amount of an asset or asset group may not be recoverable. Recoverability of intangible assets with estimable lives and other long-lived assets is measured by a comparison of the carrying amount of an asset or asset group to future net undiscounted pretax cash flows expected to be generated by the asset or asset group. If these comparisons indicate that an asset is not recoverable, the impairment loss recognized is the amount by which the carrying amount of the asset or asset group exceeds the related estimated fair value. Estimated fair value is based on either discounted future pretax operating cash flows or appraised values, depending on the nature of the asset. Judgment is required to estimate future operating cash flows.

Recent Accounting Pronouncements

ASU 2010-29. In December 2010, the FASB issued clarification of the accounting guidance related to disclosure of pro forma information for business combinations that occur in the current reporting period. The guidance requires companies to present pro forma information in their comparative financial statements as if the acquisition date for any business combination that occurred in the current reporting period had occurred at the beginning of the prior year reporting period. The Company adopted this guidance effective January 1, 2011. ASU 2010-29 is a disclosure only clarification and its adoption had no impact on the Company’s financial condition or results of operation. The Company has included the disclosures required pursuant to this guidance in this Report.

ASU 2011-04. In May 2011, the FASB issued ASU 2011-04, which amends ASC Topic 820, *Fair Value Measurements and Disclosures*, to achieve common fair value measurement and disclosure requirements under GAAP and International Financial Reporting Standards (“IFRS”). This standard gives clarification for the highest and best use valuation concepts. The ASU also provides guidance on fair value measurements relating to instruments classified in stockholders’ equity and instruments managed within a portfolio. Further, ASU 2011-04 clarifies disclosures for financial instruments categorized within level 3 of the fair value hierarchy that require companies to provide quantitative information about unobservable inputs used, the sensitivity of the measurement to changes in those inputs, and the valuation processes used by the reporting entity. The Company is currently evaluating the newly prescribed disclosures but does not expect they will have a material impact on the consolidated financial statements.

ASU 2011-05. In June 2011, the FASB issued ASU 2011-05, which amends the guidance in Topic 220, “Comprehensive Income,” by eliminating the option to present components of other comprehensive income (“OCI”) in the statement of stockholders’ equity. Instead, the guidance now requires entities to present all non-owner changes in stockholders’ equity either as a single continuous statement of comprehensive income or as two separate but consecutive statements of income and comprehensive income. The components of OCI have not changed nor has the guidance on when OCI items are reclassified to net income. Similarly, ASU 2011-05 does not change the guidance to disclose OCI components gross or net of the effect of income taxes, provided that the tax effects are presented on the face of the statement in which OCI is presented, or disclosed in the notes to the financial statements. The Company adopted this guidance effective January 1, 2012. The adoption of this guidance is not expected to have an impact on the Company's consolidated financial statements.

ASU 2011-8. In September 2011, the FASB issued ASU 2011-8, which amends ASC 350, *Intangibles-Goodwill and Other.* The amendments in this ASU give companies the option to first perform a qualitative assessment to determine whether it is more likely than not (a likelihood of more than 50.0%) that the fair value of a reporting unit is less than its carrying amount. If a company concludes that this is the case, it must perform the two-step goodwill impairment test. Otherwise, a company is not required to perform this two-step test. Under the amendments in this ASU, an entity has the option to bypass the qualitative assessment for any reporting unit in any period and proceed directly to performing the first step of the two-step goodwill impairment test. The Company adopted this guidance effective January 1, 2012. The adoption of this guidance is not expected to have an impact on the Company's consolidated financial statements.

ASU 2011-11. In December 2011, the FASB issued ASU 2011-11. The amendments in this ASU require companies to disclose information about offsetting and related arrangements to enable users of its financial statements to understand the effect of those arrangements on its financial position. The ASU is required to be applied retrospectively for all prior periods presented and is effective for annual periods for fiscal years beginning on or after January 1, 2013, and interim periods within those annual fiscal years. The adoption of this guidance is not expected to have an impact on the Company's consolidated financial statements.

4. Long-term debt The Company's long-term debt consisted of the following as of December 31, 2012 and December 31, 2011:

	September 30, 2014	**December 31, 2013**
Loans from principals	$1,645,274	$ 1,645,274
Total Debt	$1,645,527	$ 1,645,274
Less current portion	0	0
	$1,645,527	$1,645,527

Long-term debt matures as follows:

Years	**September 30, 2013 Amount**	**December 31, 2013 Amount**
2012	$0	$0
2013	0	0
2014	0	0
2015	0	0
2016	0	0
Thereafter	$1,645,527	$1,645,527
	$1,645,527	$1,645,527

5. Line of Credit

The Company currently finances its operations through loans form Investors and issuance of restricted common in lieu of cash payments. No new funding source has been obtained for the Company.

6. Stockholders' Equity

Capital Structure

The Company is also authorized to issue 800 million shares of preferred stock. As of September 30, 2014 and December 31, 2013, there were 533,464.967 and 452,818,547 shares of common stock issued and outstanding, respectively. As of September 30, 2014 and December 31, 2013, there were 50,000,000 shares of Preferred Series A and 200,000,000 shares of Preferred Series B shares issued and outstanding at both periods..

Common Stock Issuances

Issued in Acquisition

There were no shares issued for acquisition in the periods ending September 30, 2014 and December 31, 2013.

Issued for Services

On April 3, 2014 the Company issued 3,000,000 and 22,625,900 shares of Common Stock to Vrej Khacachadurin and LA Financial Equities respectively in the settlement of a single claim, Blaine Nabors was issued 750,000 shares on May 9, 2014 for consulting services and 40,000,000 shares to Elie Sakayan on May 19, 2014 for services rendered in association with the Bulgarian field Trials. On July 19, 2014 the Company issued 7,404,400 for services rendered under an employment contract. On August 20, 2014 the Company issued 3,766,120 and 3,400,000 shares to Camelot financial Group, Inc. and Uncommoncents, Inc. for consulting services rendered during the quarter ended September 30, 2014.

In 2013 the Company issued 500,000 shares to Todd Hart for a $5,000 payment made directly to one of the Company’s vendors on April 17. On September 11, 2013 the Company issued 6,000,000 shares to Alie Chang as negotiated in regards to extending the terms of the $300,000.00 note payable. On September 19 the Company issued 722,222 shares in settlement of a claim by World Financial Capital. Between September 26 and October 10 the company issued to Dimitar Savov 8,000,000 shares. The issued shares, which are restricted as to transferability, were valued at $60,000.00 reflecting the cost of the field trial for the patented treatments for Aids and Hepatitis C in Bulgaria, which represented the negotiated value of the services. All of the issuances were made in reliance on Section 4(2) of the Securities Act of 1933, as amended, and were made without general solicitation or advertising. The recipients represented to the Company that the securities were being acquired for investment purposes.

Issued for Cash

On January 16 the Company issued 3,000,000 shares and 500,000 shares to Volen Siderov and Mandjoukoov SJSC respectively under separate subscription agreements for $4,050 and $2,500. There were no shares issued for cash in the years ending December 31, 2013.

7. Stock Based Compensation

There was no stock based compensation in the periods ended September 30, 2014, December 31, 2013 or December 31, 2012.

8. Earnings Per Share (“EPS”)

The following table sets forth the computation of basic and diluted income per share for the periods ended September 30, 2014 and December 31, 2013. Basic earnings per common share is calculated by dividing net income available to common shareholders by the weighted average number of shares of common stock outstanding during the period.

	For the periods ending	
	September 30,	December 31,
	2014	**2013**
Basic (Loss) Earnings Per Share		
Undistributed net (loss) income	($431,281)	($662,280)
Less: Dividends declared	-	-
Basic undistributed net (loss) income –attributable to common shares	($431,281)	($662,280)
Denominator:		
Basic weighted average shares outstanding	478,427,914	441,345,001
Basic (Loss) Earnings Per Share — attributable to common shares	$ (0.00)	$ (0.00)

9. Income taxes

The Company has experienced net losses for the periods ended September 30, 2014 and December 31, 2013 and no tax liability has been reported.

Uncertain Tax Positions

The Financial Accounting Standards Board issued Interpretation No. 48, "Accounting for Uncertainty in Income Taxes - an interpretation of FASB Statement No. 109, Accounting for Income Taxes" ("FIN No. 48") which was effective for the Company on January 1, 2007. FIN No. 48 addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under FIN No. 48, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities based on the technical merits of the position. The tax benefits recognized in the financial statements from such position should be measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate settlement. FIN No. 48 also provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods and disclosure requirements. The company has not had a tax audit for its open tax years 2008 through 2011.

10. Related Party Transactions

The President of IMMB, Harry H. Zhabilov, is the guarantor on the lease for the facility in which the Company operates. In the April of 2013 the Company entered into a capital lease on an automobile at Market Value with Mr. Zhabilov for $11,000.00. During the quarter ended September 30, 2014 the Company repaid $2,500.00 on the outstanding balance of Loans from Harry Zhabilov. There were no other material related party transactions.

11. Concentrations and Risk

There is no concentration of clients.

12. Commitments and Contingencies

Legal Proceedings

The Company is currently not a party in any legal matters arising from its ordinary course of operations.

13. Subsequent Events

The Company's treatments entered into Field Trials in Bulgaria for 50 patients. The Company expects to have the results of these field trials in the first or second quarter of 2015.

On October 21, 2014 the Company issued 3,000,000 restricted shares to Princessa Holding under a subscription agreement for $7,000.00 or $.00233 per share.

On October 21, 2014 the Company issued 6,000,000 restricted shares to Camelot Financial Group, LLC for services rendered.

On October 21, 2014 the Company announced it had successfully completed negotiations with Uldic Investment Pvt. Ltd. (Uldic), located in Zimbabwe, to pursue the development of market opportunities related to the deadly Ebola virus, and to conduct human clinical trials using the Company's HIV/AIDS and Hepatitis C virus treatment, Immune Therapeutic Vaccine-1 (ITV-1), in Sub-Saharan West Africa. The development of this treatment will take time and resources as has the HIV/Aids and Hepatitis C treatment currently under study in Bulgaria. The Company understands from experience that bringing a drug/treatment to market is an arduous process which is scrutinized at every step by the regulatory agencies tasked with this responsibility.